MeSH tree: N06.850.520.830.998
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors responded to neoadjuvant immunochemotherapy (ICT) and who underwent less extensive surgery had high disease-free survival and organ ...
4 hours ago
0
0
Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) with moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate-risk ...
Aug 25, 2026
0
7
The cost-effectiveness of the immunotherapy drug pembrolizumab for patients with locally advanced head and neck squamous cell carcinoma may depend on biomarker results, according to a new study.
Aug 10, 2026
0
5
Community gathering places, where residents lead group activities, have been promoted across Japan as part of long-term care prevention efforts to extend healthy life expectancy. These often involve exercise and social interaction ...
Jul 31, 2026
0
6
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab ...
Jul 30, 2026
0
8
An international team of researchers led by the Barcelona Institute for Global Health (ISGlobal) and the University of Bonn—with participation from the Barça Innovation Hub (BIHUB), FC Barcelona's medical department and the ...
Jul 28, 2026
0
7
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration ...
Jul 16, 2026
0
9
Results of the Phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine ...
Jul 7, 2026
0
7
For patients with clear-cell renal cell carcinoma, pembrolizumab-belzutifan yields significantly higher disease-free survival, according to a study published in the July 2 issue of the New England Journal of Medicine.
Jul 6, 2026
0
5
For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according ...
Jul 2, 2026
0
3
